OCX 191

Drug Profile

OCX 191

Alternative Names: 3-AP; NSC 663249; NSC#663249; NTO-1151; OCX-0191; Triapine

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer National Cancer Institute (USA); Ology Bioservices; Trethera; Vion Pharmaceuticals
  • Class Antineoplastics; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Ribonuclease inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical cancer; Gynaecological cancer; Solid tumours
  • Preclinical Leukaemia
  • No development reported Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Haematological malignancies; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Discontinued Cancer; Cancer metastases; Hepatitis B; Herpes simplex virus infections; HIV infections

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 05 Jan 2017 Preclinical trials in Leukaemia (Combination therapy) in USA (unspecified route)
  • 05 Jan 2017 Trethera plans a phase I trial in Leukaemia (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top